McKesson names new independent directors to board
SAN FRANCISCO —McKesson has elected Donald R. Knauss and Susan Salka as new independent directors, effective Oct. 20, bringing the size of the board of directors to 11.
“Don and Susan are both terrific additions to the McKesson Board,” stated John H. Hammergren, chairman and CEO, McKesson Corp. “Don will bring strong international business management and retail expertise, while Susan brings a deep understanding of emerging trends in healthcare services. The addition of Don and Susan to the Board reflects our ongoing commitment to refreshing and strengthening the diversity of our Board and maintaining industry-leading governance practices.”
Knauss has served as chairman and CEO of The Clorox Co. since October 2006. Beginning Nov. 20, he will serve as chairman only, in a newly created executive chairman role. He was EVP of The Coca-Cola Co. and president and COO for Coca-Cola North America from February 2004 until September 2006. Prior to his employment with The Coca-Cola Co., he held various positions in marketing and sales with PepsiCo and Procter & Gamble and served as an officer in the United States Marine Corps. He is also a director of the Kellogg Co. and a member of the board of trustees of both Morehouse College and the University of San Diego. He was formerly a director of URS Corp.
Salka has served as CEO and president of AMN Healthcare Services since 2005, and a director of the company since 2003. She has served in several other executive roles since joining the company in 1990, including COO, CFO and SVP of business development. Salka is also a director of The Campanile Foundation at San Diego State University. She was formerly a director of Beckman Coulter, Playtex Products, University of California San Diego’s Sulpizio Cardiovascular Center and the BIOCOM Institute.
The Board has appointed Knauss and Salka as members of its Audit Committee and its Governance Committee.
Care4Today Mobile Health Manager launches new Patient Dashboard for healthcare providers
SAN DIEGO — Care4Today Mobile Health Manager, a platform designed to support and motivate people to stay on schedule with their medications, has announced the launch of a patient dashboard for health care providers and pharmacies to provide timely monitoring of self-reported medication adherence for their patients.
Janssen Healthcare Innovation, part of Janssen Research & Development, announced the new feature as well as an expanded Spanish-language version from the main stage at the Health 2.0 Fall Conference in Santa Clara.
With the Care4Today Mobile Health Manager Patient Dashboard, patients can opt in to provide their physician with a view of their ongoing medication adherence. Now, if a patient misses a dose, the physician or care provider can take appropriate action if necessary.
Care4Today Mobile Health Manager includes an up-to-date database containing 40,000 FDA-approved medications and 20,000 images inclusive of generic and brand name medications. Care4Today Mobile Health Manager uses a color-coded system to prompt patients when it is time to take their medication. Each reminder message prompts a response that is recorded in the user’s adherence report. The app is a secure, two-way messaging platform that works on almost all mobile phones including basic feature phones.
To meet the health care needs of the more than 37 million people in the United States who speak Spanish, the new version includes a Spanish-language option. The Care4Today Mobile Health Manager Spanish platform has the same functionality, including the new Patient Dashboard for providers.
Other features designed to motivate and support patient adherence:
• Care4Family: Is a tool for caregivers to remotely monitor their family member or loved one’s medication adherence and encourage them to stay on schedule. It provides caregivers with the information about a family member missing a dose so appropriate encouragement to stay on the medication regimen can be given.
• Care4Charity: Through this feature, Care4Today Mobile Health Manager users can select from several charities that will receive a 25-cent donation from Janssen Healthcare Innovation for each day through June 2015 in which they take all their medications. The charities include American Cancer Society, AIDS United, American Diabetes Association and Save the Children. Janssen Healthcare Innovation has committed a minimum donation of $20,000 to each charity and a maximum additional donation of $50,000 to the Care4Charity program.
Telehealth provider Teladoc secures $50M in funding to fuel growth
DALLAS — Telehealth provider Teladoc has secured a $50 million round of equity funding led by Palo Alto, Calif.-based Jafco Ventures, a technology venture capital firm.
“Teladoc has experienced phenomenal growth. After doubling revenue in each of the last two years, we look to accelerate this trend,” stated Jason Gorevic, CEO of Teladoc. “This sizeable investment will allow us to quickly develop new products and services that deliver additional value for our customers while simultaneously expanding into new markets and distribution channels. Our goal is to extend our significant lead in the industry such that Teladoc is the de facto brand in Telehealth.”
Teladoc stated that it will continue to pursue growth organically and through additional strategic partnerships and targeted acquisitions. The company is anticipating record-setting growth in January 2015 on the heels of its strongest selling season ever.
This year, Teladoc is on target to complete more than a quarter-million medical consults across the United States while continuing to maintain an average physician callback time of less than 16 minutes. Teladoc services are used by some of the country’s largest companies and health insurers including Blue Shield of California; Cash America; Gallup; Highmark, Inc.; Ignite Restaurants, the holding company for Romano’s Macaroni Grill, Brick House Tavern + Tap and Joe’s Crab Shack; Rent-A-Center; and T-Mobile.
Jafco is joined by other new investors, including FLAG Capital Management, Greenspring Associates, Mellon and QuestMark Partners, as well as its current investors Cardinal Partners, HLM Venture Partners, Kleiner Perkins Caufield and Byers, New Capital Partners and Trident Capital to complete Teladoc’s $50 million round of funding.